NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
galectintherapeutics.comGalectin Therapeutics plans to share additional results from the NAVIGATE trial, including specialized biomarker analyses, in the second quarter of 2025, emphasizing belapectin's potential in treating MASH cirrhosis.
clinical readoutGalectin Therapeutics is expected to complete its Phase 2b/3 clinical trial of belapectin for the prevention of esophageal varices in patients with NASH cirrhosis by September 30, 2025. The study evaluates the efficacy and safety of belapectin, a galectin-3 inhibitor, in patients with nonalcoholic steatohepatitis (NASH) cirrhosis and portal hypertension. Successful results could support regulatory filings for belapectin in this indication.
trial completion